BioCentury

7:00 AM GMT, Apr 30, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Emerging Company Profile

Vascular Magnetics: A long-term force

Drug-eluting stents were developed to better reduce restenosis compared with bare-metal stents following procedures like angioplasty, but for many patients neither of these interventions is effective long term. Vascular Magnetics Inc. is developing drug-loaded magnetic particles to reduce restenosis rates by delivering higher doses of anti-restenotic drugs than drug-eluting stents.

PAD is treated with angioplasty followed by a bare-metal or drug-eluting stent. According to co-founder, President and COO Richard Woodward, 20-40%

Read the full 705 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.